Published in Int J Mol Sci on August 07, 2015
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol (2016) 0.81
Four Aromatic Sulfates with an Inhibitory Effect against HCV NS3 Helicase from the Crinoid Alloeocomatella polycladia. Mar Drugs (2017) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol (2000) 5.26
C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun (1995) 3.09
Assembly of infectious hepatitis C virus particles. Trends Microbiol (2010) 2.36
The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol (1996) 2.30
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
Fibrosis and disease progression in hepatitis C. Hepatology (2002) 2.11
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol (2006) 1.77
Viral and cellular RNA helicases as antiviral targets. Nat Rev Drug Discov (2005) 1.59
Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem Biophys Res Commun (1996) 1.57
Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol (1998) 1.54
Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: induction of large bowel, liver and stomach neoplasms. Carcinogenesis (1990) 1.24
Hypericins as potential leads for new therapeutics. Int J Mol Sci (2010) 1.23
DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur J Biochem (1997) 1.22
Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutat Res (1983) 1.21
Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol (2009) 1.01
Real-time monitoring of RNA helicase activity using fluorescence resonance energy transfer in vitro. Biochem Biophys Res Commun (2010) 0.92
Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase. J Enzyme Inhib Med Chem (2013) 0.89
Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models. Oncotarget (2014) 0.87
Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res (2002) 0.87
Amidinoanthracyclines - a new group of potential anti-hepatitis C virus compounds. Biol Chem (2009) 0.86
A fluorescence-based screening assay for identification of hepatitis C virus NS3 helicase inhibitors and characterization of their inhibitory mechanism. Methods Mol Biol (2015) 0.85
High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem Biophys Res Commun (2009) 0.83
Sennidin stimulates glucose incorporation in rat adipocytes. Life Sci (2006) 0.82
Aurintricarboxylic acid modulates the affinity of hepatitis C virus NS3 helicase for both nucleic acid and ATP. Biochemistry (2013) 0.82
The natural compound Alizarin as an osteotropic drug for the treatment of bone tumors. J Orthop Res (2012) 0.81
Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis (1991) 0.80
Antitumour and immunosuppressive activity of hydroxyanthraquinones and their glucosides. Folia Biol (Praha) (1977) 0.77
Identification and biochemical characterization of halisulfate 3 and suvanine as novel inhibitors of hepatitis C virus NS3 helicase from a marine sponge. Mar Drugs (2014) 0.77
Toxicity and tumorigenicity of purpurin, a natural hydroxanthraquinone in rats: induction of bladder neoplasms. Cancer Lett (1996) 0.77
Genotoxicity in the hepatocyte/DNA repair test and toxicity to liver mitochondria of 1-hydroxyanthraquinone and several dihydroxyanthraquinones. Cell Biol Toxicol (1986) 0.77
Retreatment with peginterferon and ribavirin in chronic hepatitis C. World J Gastroenterol (2015) 0.76
Structure-activity relationships of anthraquinones in the decrease of intestinal motility. J Pharm Pharmacol (2000) 0.76
The synergistic effect of 1-hydroxyanthraquinone on methylazoxymethanol acetate-induced carcinogenesis in rats. Carcinogenesis (1991) 0.76
Identification and biochemical characterization of halisulfate 3 and suvanine as novel inhibitors of hepatitis C virus NS3 helicase from a marine sponge. Mar Drugs (2014) 0.77
PBDE: structure-activity studies for the inhibition of hepatitis C virus NS3 helicase. Molecules (2014) 0.77
Four Aromatic Sulfates with an Inhibitory Effect against HCV NS3 Helicase from the Crinoid Alloeocomatella polycladia. Mar Drugs (2017) 0.75
Two Furanosesterterpenoids from the Sponge Luffariella variabilis. Mar Drugs (2017) 0.75
Meta-Analysis of Fecal Microbiota and Metabolites in Experimental Colitic Mice during the Inflammatory and Healing Phases. Nutrients (2017) 0.75